Ultra Efficacy
Retatrutide
Next-Generation Weight Loss
Starting at $300
The world's first triple incretin agonist — activating GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 data produced weight loss results that rival bariatric surgery.
GLP-1 + GIP + Glucagon
Retatrutide is the first investigational drug to simultaneously activate three distinct metabolic hormone receptors — creating a synergistic metabolic response more powerful than any existing approved therapy.
24.2% average weight loss
Phase 2 data produced 24.2% mean body weight reduction at 48 weeks — the highest ever reported for a pharmacological agent in a controlled trial, approaching the outcomes of bariatric surgery.
Glucagon activation advantage
Uniquely, retatrutide activates the glucagon receptor — increasing resting energy expenditure and promoting fat oxidation. This 'energy out' mechanism is absent in GLP-1 and dual-agonist therapies.
The Science, in Full Detail
We believe patients deserve to understand exactly how and why their treatment works.
Three receptors. One weekly injection.
Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. Each pathway contributes a distinct mechanism of action — together producing a metabolic effect far beyond what single or dual-agonist therapies can achieve.
Get StartedGLP-1 Pathway
- Slows gastric emptying — food moves through your stomach more slowly, extending fullness
- Signals the brain's satiety centers to reduce hunger and 'food noise'
- Glucose-dependent insulin release (safe blood sugar control)
- Reduces inappropriate glucagon secretion
GIP Pathway
- Enhances the GLP-1 signal — amplifies satiety signaling
- Improves fat cell metabolism and reduces fat storage efficiency
- Supports superior body composition outcomes vs. GLP-1 alone
Glucagon Pathway
- Increases resting metabolic rate and energy expenditure
- Promotes mobilization and oxidation of fat stores
- Improves body composition — preserves lean mass
Full Transparency
Side effects, honestly
We believe informed patients get better outcomes. Here's exactly what clinical trials report — with context on how common each effect is and how to manage it.
Nausea
Very CommonSeverity: Mild–Moderate
Most intense during titration. Usually resolves within 2–3 weeks of each dose increase. Eating smaller, more frequent meals helps.
Constipation
CommonSeverity: Mild
GI motility slowing is part of mechanism. Adequate hydration, fiber, and physical activity help.
Vomiting
CommonSeverity: Mild–Moderate
More common at higher doses or fast titration. Slowing escalation pace reduces incidence significantly.
Decreased Appetite
Very CommonSeverity: Intended effect
Primary mechanism of action. Providers monitor to ensure adequate protein and nutrition intake.
Fatigue
CommonSeverity: Mild
Usually transient in first weeks after dose increase. Ensuring sufficient caloric intake helps.
Diarrhea
CommonSeverity: Mild
Often transient during dose escalation. Stay well-hydrated and consider fiber supplementation.
Questions about Retatrutide
Detailed answers to the most important questions
Transparent Pricing
Consultation Fees
Physician-guided care with complete pricing clarity.
Generic Consultation
Includes Any & All Services
First Visit
$400
Follow-Up
$150
- Complete health assessment
- All service areas covered
- Personalized treatment plan
- Prescription if appropriate
Specialized Consultation
Skin, Hair, Wellness, Labs, Galleri
First Visit
$300
Follow-Up
$150
- Focused specialty review
- Lab analysis included
- Targeted treatment approach
- Follow-up protocol
Peptide Consultation
Weight loss & metabolic therapies
First Visit
$50
Follow-Up
$30
- Metabolic assessment
- GLP-1 or peptide evaluation
- Dosing strategy
- Prescription included